Menu
Search
|

Menu

Close
X

HTG Molecular Diagnostics Inc HTGM.OQ (NASDAQ Stock Exchange Capital Market)

0.83 USD
-0.01 (-1.28%)
As of 4:00 PM EDT
Previous Close 0.84
Open 0.85
Volume 23,453
3m Avg Volume 41,211
Today’s High 0.88
Today’s Low 0.83
52 Week High 5.45
52 Week Low 0.75
Shares Outstanding (mil) 11.45
Market Capitalization (mil) 21.52
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY19
9
FY18
22
FY17
15
FY16
5
EPS (USD)
FY19
-0.355
FY18
-0.607
FY17
-1.939
FY16
-3.674
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
3.91
7.91
Price to Book (MRQ)
vs sector
--
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
--
14.55
LT Debt to Equity (MRQ)
vs sector
--
10.20
Return on Investment (TTM)
vs sector
-158.24
14.48
Return on Equity (TTM)
vs sector
-1,928.83
15.78

EXECUTIVE LEADERSHIP

Timothy Johnson
Executive Chairman of the Board, Since 2019
Salary: $426,250.00
Bonus: $200,000.00
John Lubniewski
President, Chief Executive Officer, Director, Since 2019
Salary: $327,230.00
Bonus: $100,000.00
Shaun McMeans
Chief Financial Officer, Senior Vice President, Principal Financial Officer, Since 2019
Salary: $288,608.00
Bonus: $50,000.00
Laura Godlewski
Principal Accounting Officer, Since 2019
Salary: --
Bonus: --
Ann Hanham
Lead Independent Director, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Advanced Medical Equipment & Technology
Address:

3430 E Global Loop
TUCSON   AZ   85706-5009

Phone:

HTG Molecular Diagnostics, Inc. is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company's HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Company's HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Company's HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument.

SPONSORED STORIES